The particularly low rate of EpCAM positivity in mesotheliomas (26%), hepatocellular carcinomas (14.3%), and squamous cell carcinomas of various sites of origin (59.0–98.3%, mean 84.0%) is in the lower range of previous studies describing EpCAM positivity on average in 32% of hepatocellular carcinomas, and somewhat higher compared to previous studies describing EpCAM positivity on average in 10% of mesotheliomas and 66% of squamous cell carcinomas (Supplementary Table S2). This evidence concerns the gene EPCAM and squamous cell carcinoma.